InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (1 ops.)
Insider track record
Board DirectorDisclosed buys
2
Disclosed sells
1
T+90 hit rate
0%
T+90 mean return
-12.4%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Nolan Sean P., Director. Insider active across 3 companies, notably Taysha Gene Therapies, Inc.. Aggregated, 12 filings have been logged. Breakdown: 2 buys · 1 sell. Total volume traded: €942k. History available since 20 May 2021. The latest transaction was disclosed on 13 May 2026 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Nolan Sean P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations12 total
2,047 shares@ US$90.350.0004% mcap32.8% of flowCommon StockSEC:0001569926-26-000012:0
136,789 shares@ US$4.75100.0% of flowCommon StockSEC:0001569926-26-000008:0
1,008,000 shares0Common StockSEC:0001569926-26-000002:0
2,882 shares@ US$64.1817.1% of flowCommon StockSEC:0000740260-25-000175:0
892,500 shares0Common StockSEC:0001415889-25-000599:0
3,648 shares@ US$47.9616.7% of flowCommon StockSEC:0000740260-24-000162:0
1,184,688 shares0Common StockSEC:0001209191-24-000807:0
444,444 shares@ US$0.9089.6% of flowCommon StockSEC:0001209191-23-046150:0
Canonical exit: 14 Nov 2023 (T+90)
3,835 shares@ US$45.6316.6% of flowCommon StockSEC:0000740260-23-000123:0
3,056 shares@ US$57.250.0004% mcap34.4% of flowCommon StockSEC:0000740260-22-000111:0
3,158 shares0Common StockSEC:0000740260-21-000134:0
1,170 shares@ US$22.355.5% of flowCommon StockSEC:0001209191-21-035165:0
Canonical exit: 18 Aug 2021 (T+90)
12 of 12 declarations
About Nolan Sean P.
Nolan Sean P. is Administrateur and has 12 filings in total. Across the 12 sampled filings, the activity runs from 2021-05-24 to 2026-05-15, with EUR 389209 of purchases and EUR 552760 of sales. The main filings concern Taysha Gene Therapies, Inc. and Ventas, Inc., and the modal transaction nature is Attribution.
